In crowded MS market, Merck KGaA's Mavenclad now offsets Rebif decline

14th November 2019 Uncategorised 0

Competition in the multiple sclerosis field has stepped up significantly, thanks to several recent drug launches. But in that fray, Merck KGaA’s Mavenclad can be counted as one successful rollout—at least so far—as its third-quarter sales offset losses for the German drugmaker’s older interferon med Rebif.

More: In crowded MS market, Merck KGaA's Mavenclad now offsets Rebif decline
Source: fierce